<SEC-DOCUMENT>0001829126-25-003351.txt : 20250505
<SEC-HEADER>0001829126-25-003351.hdr.sgml : 20250505
<ACCEPTANCE-DATETIME>20250505060953
ACCESSION NUMBER:		0001829126-25-003351
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250505
DATE AS OF CHANGE:		20250505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nexalin Technology, Inc.
		CENTRAL INDEX KEY:			0001527352
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				275566468
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-286711
		FILM NUMBER:		25910789

	BUSINESS ADDRESS:	
		STREET 1:		1776 YORKTOWN
		STREET 2:		SUITE 550
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77056
		BUSINESS PHONE:		(832) 260-0222

	MAIL ADDRESS:	
		STREET 1:		1776 YORKTOWN
		STREET 2:		SUITE 550
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77056
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>nexalintech_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
   <HEAD>
      <TITLE></TITLE>
   </HEAD>
   <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
pursuant to Rule&nbsp;424(b)(5)</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
      No. 333-286711</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>PROSPECTUS
SUPPLEMENT</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>(t</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o
      the Prospectus dated April&nbsp;23, 2025)</FONT></B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Up
      to $3,100,000</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEXALIN
      TECHNOLOGY, INC.</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><IMG SRC="img_001.jpg" ALT="" STYLE="height: 72px; width: 250px"></P>




      <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
      Stock</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>





<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
      April&nbsp;23, 2025, we entered into an Equity Distribution Agreement (the &ldquo;ATM Sales Agreement&rdquo;) with Maxim Group
      LLC (the &ldquo;Sales Agent&rdquo;), relating to shares of our common stock, par value $0.001 per share. In accordance with the
      ATM Sales Agreement, we were authorized to offer and sell shares of our common stock having an aggregate offering price of up to
      $9,777,825 from time to time through the Sales Agent. On May&nbsp;5, 2025, we entered into Amendment No. 1 to the ATM Sales Agreement
      (the &ldquo;First Amendment&rdquo;) to reduce the aggregate offering price of our shares of common stock that we may sell through
      the Sales Agent to up to $3,100,000. Each reference to the term &ldquo;ATM Sales Agreement&rdquo; in this prospectus supplement
      is hereby amended to refer to the ATM Sales Agreement after giving effect to the First Amendment.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
      common stock trades on the Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;NXL.&rdquo; The last reported sale
      price of our common stock on Nasdaq on May&nbsp;2, 2025 was $1.79 per share.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
      At-the-Market (&ldquo;ATM&rdquo;) program will allow us to raise capital by selling shares of our common stock in open market transactions
      at our discretion. Unlike in underwritten public offerings, sales under ATM programs are not marketed, they are made at prevailing
      market prices, and they are generally less dilutive to stockholders than marketed offerings that generate the same net proceeds
      because (i) they are typically less expensive to transact than marketed offerings and (ii) they can be executed without a discount
      to the prevailing market price of the stock that is typical in marketed offerings. Our Board of Directors has concluded that, at
      this time, it is in our best interest to have an ATM program available and to be used at our discretion for capital raising, since
      it enables us to determine the timing, quantity, and pricing of sales. Under the ATM Sales Agreement, we are not obligated to sell
      any shares, but we may issue and sell shares of our common stock having an aggregate gross sales price of up to $3,100,000 through
      the Sales Agent.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
      to General Instruction I.B.6 of Form S-3, in no event will we sell our securities in public primary offerings with a value exceeding
      more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million. As of May&nbsp;2,
      2025, the aggregate market value of our outstanding common stock held by non-affiliates, or the public float, was approximately
      $26,843,917, based on 10,824,160 shares of our outstanding common stock that were held by non-affiliates on such date and a price
      of $2.48 per share, which was the price at which our common stock was last sold on the Nasdaq Capital Market on March&nbsp;20,
      2025, calculated in accordance with General Instruction I.B.6 of Form S-3. We have not offered any securities pursuant to General
      Instruction I.B.6 of Form S-3 during the twelve-month period that ends on and includes the date hereof.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
      of our common stock covered by this prospectus supplement may be sold by any method deemed to be an &ldquo;at the market offering&rdquo;
      as defined in Rule&nbsp;415(a)(4) under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;). When they receive
      a sale order from us, the Sales Agents have agreed to use commercially reasonable efforts consistent with normal trading and sales
      practices to execute the order on mutually agreed terms. There is no arrangement for funds to be received in any escrow, trust,
      or similar arrangement.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      compensation payable to the Sales Agent for sales of common stock sold pursuant to the ATM Sales Agreement will be 3% of the gross
      proceeds of the sales price of common stock sold. The Company shall reimburse the Sale Agent upon request for its actual, reasonable
      and documented out-of-pocket costs and expenses incurred in connection with the ATM Sales Agreement, as provided herein. We anticipate
      no other commissions or material expenses for sales under the ATM Sales Agreement. The orders will be executed at price limits
      imposed by us.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
      though this prospectus supplement does not relate to a marketed offering of our common stock, in connection with the sale of common
      stock under the ATM Sales Agreement, the Sales Agent will each be deemed to be an &ldquo;underwriter&rdquo; within the meaning
      of the Securities Act, and the compensation of the Sales Agent will be deemed to be underwriting commissions or discounts. We have
      agreed to indemnify the Sales Agent against certain civil liabilities, including liabilities under the Securities Act. See the
      section titled &ldquo;Plan of Distribution&rdquo; on page S-12 of this prospectus supplement.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
      we are an &ldquo;emerging growth company&rdquo; as defined in Section&nbsp;2(a) of the Securities Act of 1933, as amended, and
      are subject to reduced public company reporting requirements. Please read &ldquo;Implications of Being an Emerging Growth Company.&rdquo;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
      in our common stock involves certain risks. You should read carefully and consider the &ldquo;Risk Factors&rdquo; referenced on
      page S-5 of this prospectus supplement and the risk factors described in other documents incorporated by reference herein before
      making an investment decision.</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
      the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
      upon the adequacy or accuracy of this prospectus supplement. Any representation to the contrary is a criminal offense.</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Maxim
      Group LLC</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
      date of this Prospectus Supplement is May&nbsp;5, 2025</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>TABLE
      OF CONTENTS</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: bottom; width: 90%; text-align: justify; text-indent: -0.25in; padding-left: 0.25in; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: bottom; white-space: nowrap; width: 1%; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: bottom; width: 9%; border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD>
         </TR>
         <TR STYLE="background-color: rgb(204,238,255)">
            <TD STYLE="vertical-align: bottom; text-align: justify; text-indent: -0.25in; padding-left: 0.25in; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pro_001">ABOUT THIS PROSPECTUS SUPPLEMENT AND PROSPECTUS</A></FONT></TD>
            <TD STYLE="vertical-align: bottom; white-space: nowrap; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: bottom; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD>
         </TR>
         <TR STYLE="background-color: White">
            <TD STYLE="vertical-align: bottom; text-align: justify; text-indent: -0.25in; padding-left: 0.25in; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pro_002">PROSPECTUS SUMMARY</A></FONT></TD>
            <TD STYLE="vertical-align: bottom; white-space: nowrap; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: bottom; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-2</FONT></TD>
         </TR>
         <TR STYLE="background-color: rgb(204,238,255)">
            <TD STYLE="vertical-align: bottom; text-align: justify; text-indent: -0.25in; padding-left: 0.25in; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pro_003">THE OFFERING</A></FONT></TD>
            <TD STYLE="vertical-align: bottom; white-space: nowrap; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: bottom; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-4</FONT></TD>
         </TR>
         <TR STYLE="background-color: White">
            <TD STYLE="vertical-align: bottom; text-align: justify; text-indent: -0.25in; padding-left: 0.25in; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pro_004">RISK FACTORS</A></FONT></TD>
            <TD STYLE="vertical-align: bottom; white-space: nowrap; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: bottom; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-5</FONT></TD>
         </TR>
         <TR STYLE="background-color: rgb(204,238,255)">
            <TD STYLE="vertical-align: bottom; text-align: justify; text-indent: -0.25in; padding-left: 0.25in; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pro_005">CAUTIONARY NOTE ABOUT FORWARD-LOOKING STATEMENTS</A></FONT></TD>
            <TD STYLE="vertical-align: bottom; white-space: nowrap; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: bottom; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-9</FONT></TD>
         </TR>
         <TR STYLE="background-color: White">
            <TD STYLE="vertical-align: bottom; text-align: justify; text-indent: -0.25in; padding-left: 0.25in; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pro_006">USE OF PROCEEDS</A></FONT></TD>
            <TD STYLE="vertical-align: bottom; white-space: nowrap; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: bottom; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-10</FONT></TD>
         </TR>
         <TR STYLE="background-color: rgb(204,238,255)">
            <TD STYLE="vertical-align: bottom; text-align: justify; text-indent: -0.25in; padding-left: 0.25in; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pro_007">DILUTION</A></FONT></TD>
            <TD STYLE="vertical-align: bottom; white-space: nowrap; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: bottom; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-11</FONT></TD>
         </TR>
         <TR STYLE="background-color: White">
            <TD STYLE="vertical-align: bottom; text-align: justify; text-indent: -0.25in; padding-left: 0.25in; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pro_008">PLAN OF DISTRIBUTION</A></FONT></TD>
            <TD STYLE="vertical-align: bottom; white-space: nowrap; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: bottom; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-12</FONT></TD>
         </TR>
         <TR STYLE="background-color: rgb(204,238,255)">
            <TD STYLE="vertical-align: bottom; text-align: justify; text-indent: -0.25in; padding-left: 0.25in; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pro_009">LEGAL MATTERS</A></FONT></TD>
            <TD STYLE="vertical-align: bottom; white-space: nowrap; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: bottom; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-13</FONT></TD>
         </TR>
         <TR STYLE="background-color: White">
            <TD STYLE="vertical-align: bottom; text-align: justify; text-indent: -0.25in; padding-left: 0.25in; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pro_010">EXPERTS</A></FONT></TD>
            <TD STYLE="vertical-align: bottom; white-space: nowrap; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: bottom; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-13</FONT></TD>
         </TR>
         <TR STYLE="background-color: rgb(204,238,255)">
            <TD STYLE="vertical-align: bottom; text-align: justify; text-indent: -0.25in; padding-left: 0.25in; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pro_011">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></TD>
            <TD STYLE="vertical-align: bottom; white-space: nowrap; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: bottom; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-13</FONT></TD>
         </TR>
         <TR STYLE="background-color: White">
            <TD STYLE="vertical-align: bottom; text-align: justify; text-indent: -0.25in; padding-left: 0.25in; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#pro_012">INFORMATION INCORPORATED BY REFERENCE</A></FONT></TD>
            <TD STYLE="vertical-align: bottom; white-space: nowrap; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: bottom; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-14</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>You
      should rely only on the information contained in, or incorporated by reference into, this prospectus supplement, the accompanying
      prospectus or any applicable free writing prospectus in making your investment decisions. Neither we nor the Sales Agent have authorized
      anyone to provide you with different, inconsistent or additional information. If anyone provides you with different, inconsistent
      or additional information, you should not rely on it. This prospectus supplement, the accompanying prospectus and any applicable
      free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the
      registered securities to which they relate, nor does this prospectus supplement, the accompanying prospectus and any applicable
      free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any
      person to whom it is unlawful to make such an offer or solicitation in such jurisdiction. You should assume the information contained
      in this prospectus supplement, the accompanying prospectus any applicable free writing prospectus or the documents incorporated
      by reference herein are accurate only as of the respective dates of each such document or on the date or dates which are specified
      in these documents. Our business, financial condition and prospects may have changed since such dates.</B></FONT></P>
      <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pro_001"></A>ABOUT
      THIS PROSPECTUS SUPPLEMENT AND PROSPECTUS</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
      prospectus supplement and the accompanying prospectus are part of a &ldquo;shelf&rdquo; registration statement on Form S-3 (File
      No. 333-286711) that we initially filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;) on April&nbsp;23, 2025,
      and that was declared effective by the SEC on April&nbsp;29, 2025. Under the shelf registration process, we may from time to time
      offer and sell any combination of the securities described in the accompanying prospectus up to a total dollar amount of $3,100,000,
      of which this offering is a part. Under this prospectus supplement, we may offer shares of our common stock having a total aggregate
      offering price of up to $3,100,000. As of the date of this prospectus supplement, we have not sold any securities under the registration
      statement.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
      prospectus supplement describes the specific terms of this offering and also adds to, changes and updates information contained
      in the accompanying prospectus and the documents incorporated by reference herein. This prospectus supplement and the documents
      incorporated herein by reference include important information about us, the shares being offered, and other information you should
      know before investing in our common stock. The second part, the accompanying prospectus, gives more general information, some of
      which may not apply to this offering. Generally, when we refer to this &ldquo;prospectus,&rdquo; we are referring to both documents
      combined.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
      should read this prospectus supplement, the accompanying prospectus, and the documents incorporated by reference into this prospectus
      supplement that we may authorize for use in connection with this offering, in their entirety before making an investment decision.
      You should also read and consider the information in the documents to which we have referred you in the sections of this prospectus
      supplement entitled &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation of Certain Documents by Reference.&rdquo;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
      prospectus supplement describes the specific terms of the common stock we are offering and also adds to, and updates information
      contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement. To the extent
      there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained
      in the accompanying prospectus or any document incorporated by reference into this prospectus supplement that was filed with the
      SEC before the date of this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement.
      If any statement in one of these documents is inconsistent with a statement in in a filing we make with the SEC that adds to, updates
      or changes information contained in an earlier filing we made with the SEC &mdash; for example, a document incorporated by reference
      into this prospectus supplement &mdash; the statement in the filing we make with the SEC having the later date modifies or supersedes
      the earlier statement.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
      prospectus supplement does not contain all of the information that is important to you. You should rely only on this prospectus
      and the information incorporated or deemed to be incorporated by reference in this prospectus. We have not, and the Sales Agents
      have not, authorized anyone to provide you with information that is in addition to or different from that contained or incorporated
      by reference in this prospectus. We are not, and the Sales Agents are not, offering to sell these securities in any jurisdiction
      where the offer or sale is not permitted. You should not assume that the information contained or incorporated by reference in
      this prospectus is accurate as of any date other than as of the date of this prospectus or in the case of the documents incorporated
      by reference, the date of such documents regardless of the time of delivery of this prospectus or any sale of our common stock.
      Our business, financial condition, liquidity, results of operations, and prospects may have changed since those dates.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
      should read this prospectus supplement, the accompanying prospectus, and the documents incorporated by reference into this prospectus
      supplement that we may authorize for use in connection with this offering, in their entirety before making an investment decision.
      You should also read and consider the information in the documents to which we have referred you in the sections of this prospectus
      entitled &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation of Certain Documents by Reference.&rdquo;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
      are offering to sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted.
      The distribution of this prospectus supplement and the offering of the common stock in certain jurisdictions may be restricted
      by law. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe
      any restrictions relating to, the offering of the common stock and the distribution of this prospectus outside the United States.
      This prospectus does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to
      buy, any securities offered by this prospectus by any person in any jurisdiction in which it is unlawful for such person to make
      such an offer or solicitation.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
      further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any
      document that is incorporated by reference into this prospectus supplement and accompanying prospectus were made solely for the
      benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such
      agreement, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties
      or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not
      be relied on as accurately representing the current state of our affairs.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
      this prospectus, unless the context requires otherwise, references to &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;Nexalin&rdquo;
      or the &ldquo;Company&rdquo; refer to Nexalin Technology, Inc. and, where appropriate, its subsidiaries.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pro_002"></A>PROSPECTUS
      SUPPLEMENT SUMMARY</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
      following is a summary of selected information contained elsewhere in this prospectus supplement or incorporated by reference.
      It does not contain all of the information that you should consider before buying our securities. You should read this prospectus
      in its entirety, including the information incorporated by reference herein and therein.</I></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
      Company</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
      are a medical device company engaged in the design and developments of innovative neurostimulation products to uniquely and effectively
      help combat the ongoing global mental health epidemic. We developed an easy-to-administer medical device &mdash; referred to as
      &ldquo;Generation 1&rdquo; or &ldquo;Gen-1&rdquo; &mdash; that utilizes bioelectronic medical technology to treat anxiety, insomnia
      and depression without the need for drugs or psychotherapy. Our original Gen-1 devices are cranial electrotherapy stimulation (CES)
      devices that emit a waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration
      (the &ldquo;FDA&rdquo;) as a Class II device.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
      professionals in the United States have utilized the Gen-1 device to administer treatment to patients in clinical settings. While
      the Gen-1 device had been cleared by the FDA to treat depression, anxiety, and insomnia, three prevalent and serious diseases,
      because of the FDA&rsquo;s December&nbsp;2019 reclassification of CES devices, the Gen-1 device was reclassified as a Class II
      device for the treatment of anxiety and insomnia. We are required to file a new application under Section&nbsp;510(k) of the Federal
      Food, Drug and Cosmetic Act (&ldquo;510(k) Application&rdquo;) to be approved by the FDA for the sales and marketing of our devices
      for the treatment of anxiety and insomnia. In the FDA&rsquo;s December&nbsp;2019 reclassification ruling, the treatment of depression
      with our device will require a Class III certification and require a new PMA (premarket approval) and/or a new De Novo application
      to demonstrate safety and effectiveness.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
      we continue providing services to medical professionals to support patients&rsquo; use of the Gen-1 devices which were in operation
      prior to December&nbsp;2019, we are not making new sales or new marketing efforts of Gen-1 devices in the United States. We continue
      to derive revenue from devices which we sold or leased prior to the FDA&rsquo;s December&nbsp;2019 reclassification announcement.
      This revenue consists of monthly licensing fees and payments for the sale of electrodes and patient cables. We have paused marketing
      efforts for new sales of our Gen-1 device for treatment of anxiety and insomnia in the United States.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      waveform that comprises the basis of our &ldquo;Generation 2&rdquo; or &ldquo;Gen-2&rdquo; and new &ldquo;Generation 3&rdquo; or
      &ldquo;Gen-3&rdquo; headset devices is in Q-submission process for review by the FDA. This process allows Nexalin to get clear,
      specific, written feedback from the FDA on indications, device classification and clarity on the regulatory pathway and improves
      the efficiency and predictability of the regulatory pathway. The University of California, San Diego conducted a clinical study
      evaluating Nexalin&rsquo;s Gen-2 tACS device, which provided positive results in reducing pain in veteran patients with Mild Traumatic
      Brain Injury (mTBI). We plan to conduct clinical trials for the Gen-3 device in the U.S. and we continue to consult with the FDA
      as part of the pre-submission process. If and when we obtain FDA clearance for the Gen-3 device, we intend to extend the development
      and commercialization of our devices for sale in the U.S. and other territories, given the potential unmet demand for the treatment
      of mental health conditions.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
      determinations of the safety and efficacy of our devices in the United States are solely within the purview of the FDA.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
      aspects of our ongoing operations and clinical trials and development programs are conducted in China, through a joint venture
      entity formed under the laws of Hong Kong, Nexalin Neurohealth Company Limited (&ldquo;Joint Venture&rdquo;), with Wider Come Limited
      (&ldquo;Wider&rdquo;). We own 48% of the equity of the Joint Venture entity, and Wider owns 52% of such equity. In September of
      2021, the China National Medical Products Administration (the &ldquo;NMPA&rdquo;), the equivalent of the FDA, approved the Gen-2
      device for marketing and sale in China for the treatment of insomnia and depression. These treatment indications and clearances
      from the NMPA have allowed Wider to market and sell the Gen-2 device in China for the treatment of insomnia and depression.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
      addition to our core business model, we have also formed a Military &amp; Government Advisory Board aimed at fostering and enhancing
      relationships within and throughout United States federal government and public sector organizations, including the U.S. Department
      of Defense, U.S. Department of Veterans Affairs, and U.S. Department of Health and Human Services. In conjunction with our ongoing
      clinical trials, our goals include the broad deployment of our devices within the U.S. military and government agencies.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
      Information</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
      were incorporated in the state of Nevada on October&nbsp;19, 2010, and redomiciled in Delaware on December&nbsp;21, 2021. Our principle
      executive office is located at 1776 Yorktown, Suite 550, Houston, Texas 77056, and our telephone number is (832) 260-0222. Our
      website address is <U>www.nexalin.com</U>. The information contained on or accessible through our website is not incorporated by
      reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our
      website as part of this prospectus or in deciding whether to purchase our common stock.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
      of Being an Emerging Growth Company and Smaller Reporting Company</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
      are an &ldquo;emerging growth company,&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012 (the &ldquo;JOBS Act&rdquo;).
      We will remain an emerging growth company until the earlier of (i) the last day of the fiscal year following the fifth anniversary
      of the date of the first sale of our common stock pursuant to an effective registration statement under the Securities Act; (ii)
      the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more; (iii) the date on which
      we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed
      to be a large accelerated filer under applicable SEC rules. We expect that we will remain an emerging growth company for the foreseeable
      future, but cannot retain our emerging growth company status indefinitely and will no longer qualify as an emerging growth company
      on or before the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common stock
      pursuant to an effective registration statement under the Securities Act. For so long as we remain an emerging growth company,
      we are permitted and intend to rely on exemptions from specified disclosure requirements that are applicable to other public companies
      that are not emerging growth companies.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
      exemptions include:</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
            permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial
            statements, with correspondingly reduced &ldquo;<I>Management&rsquo;s Discussion and Analysis of Financial Condition and
            Results of Operations</I>&rdquo; disclosure;</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
            being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002,
            as amended;</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
            being required to comply with the requirement of auditor attestation of our internal controls over financial reporting;</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
            being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding
            mandatory audit firm rotation or a supplement to the auditor&rsquo;s report providing additional information about the audit
            and the financial statements;</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
            disclosure obligations regarding executive compensation; and</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
            being required to hold a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute
            payments not previously approved.</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
      have taken advantage of certain reduced reporting requirements in this prospectus. Accordingly, the information contained herein
      may be different than the information you receive from other public companies in which you hold stock.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
      emerging growth company can take advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities
      Act for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain
      accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected to avail ourselves
      of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the
      dates on which adoption of such standards is required for other public reporting companies.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
      are also a &ldquo;smaller reporting company&rdquo; as defined in Rule&nbsp;12b-2 of the Securities Exchange Act of 1934, as amended
      (the &ldquo;Exchange Act&rdquo;), and have elected to take advantage of certain of the scaled disclosure available for smaller
      reporting companies.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="pro_003"></A>THE
      OFFERING</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 27%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
            Stock offered by us:</B></FONT></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
            <TD STYLE="vertical-align: top; width: 70%"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0in; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
               of common stock having an aggregate gross sales price of up to $3,100,000.</FONT></P>
            </TD>
         </TR>
         <TR>
            <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
            <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
         <TR>
            <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
            stock outstanding after this offering:</B></FONT></TD>
    <TD>&nbsp;</TD>
            <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0in; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
               to 15,059,772 shares, assuming a sales price of $1.79 per share, which was the last reported sale price on The NASDAQ
               Capital Market on May&nbsp;2, 2025. The actual number of shares issued and outstanding will vary depending on the sales
               price under this offering.</FONT></P>
            </TD>
         </TR>
         <TR>
            <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
            <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
         <TR>
            <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Manner
            of offering:</B></FONT></TD>
    <TD>&nbsp;</TD>
            <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0in; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;At-the-market&rdquo;
               offering that may be made from time to time in the United States through or to Maxim Group LLC, acting as sale agent or
               principal. See the section entitled &ldquo;Plan of Distribution&rdquo; below.</FONT></P>
            </TD>
         </TR>
         <TR>
            <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
            <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
         <TR>
            <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
            Factors:</B></FONT></TD>
    <TD>&nbsp;</TD>
            <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0in; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
               investment in shares of our common stock involves substantial risks. You should consider the &ldquo;Risk Factors&rdquo;
               included and incorporated by reference in this prospectus, including the risk factors incorporated by reference from our
               filings with the SEC.</FONT></P>
            </TD>
         </TR>
         <TR>
            <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
            <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
         <TR>
            <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exclusive
            Sales Agent:</B></FONT></TD>
    <TD>&nbsp;</TD>
            <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0in; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maxim
               Group LLC is acting as the exclusive sale agent in connection with this offering.</FONT></P>
            </TD>
         </TR>
         <TR>
            <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
            <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
         <TR>
            <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nasdaq
            Capital Market Symbol:</B></FONT></TD>
    <TD>&nbsp;</TD>
            <TD STYLE="vertical-align: top; text-align: justify; padding-left: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NXL</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      number of shares of our common stock outstanding after the offering is based on approximately 13,327,929 shares of our Common Stock
      outstanding as of May&nbsp;2, 2025 and the sale of 1,731,843 shares of our common stock at an assumed offering price of $1.79 per
      share, the last reported sale price of our common stock on Nasdaq on May&nbsp;2, 2025, and excludes:</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,662,250
            shares of common stock issuable upon exercise of outstanding warrants issued in our initial public offering;</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,988,375
            shares of our common stock issuable upon the exercise of outstanding and vested stock options under the Company&rsquo;s 2023
            Equity Incentive Plan, as amended (the &ldquo;2023 Plan&rdquo;); and</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
            312,000 shares of our common stock that have been approved for grant under the 2023 Plan, but have not yet been issued.</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>This
      prospectus reflects and assumes no exercise of outstanding options or warrants.</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="pro_004"></A>RISK
      FACTORS</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Before
      purchasing any of the securities you should carefully consider the risk factors relating to our company described below and incorporated
      by reference in this prospectus from our Annual Report on Form 10-K for the year ended December&nbsp;31, 2024, as well as the risks,
      uncertainties, and additional information set forth in other documents incorporated by reference in this prospectus. For a description
      of these reports and documents, and information about where you can find them, see &ldquo;Where You Can Find More Information&rdquo;
      and &ldquo;Incorporation of Certain Documents By Reference.&rdquo; Additional risks not presently known or that we presently consider
      to be immaterial could subsequently materially and adversely affect our financial condition, results of operations, business, and
      prospects.</I></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Risks
      Associated with Our Capital Stock</I></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
      we are not able to comply with the applicable continued listing requirements or standards of The Nasdaq Stock Market, Nasdaq could
      delist our common stock.</I></B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
      shares of our common stock are listed on the Capital Market tier of the Nasdaq Stock Market, or Nasdaq, under the symbol &ldquo;NXL.&rdquo;
      Nasdaq has rules for continued listing, including, without limitation, minimum market capitalization, minimum stockholders&rsquo;
      equity and other requirements. In order to maintain that listing, we must satisfy minimum financial and other continued listing
      requirements and standards, including the Minimum Bid Price Rule (as discussed below) and those regarding director independence
      and independent committee requirements, minimum stockholders&rsquo; equity, and certain corporate governance requirements. There
      can be no assurances that we will be able to comply with the applicable listing standards.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Minimum
      Bid Price Requirement</I></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
      are required to maintain a minimum bid price of $1.00 per share. On May&nbsp;10, 2023, the Company received written notice from
      Nasdaq notifying the Company that it was no longer in compliance with the minimum bid price requirement for continued listing on
      Nasdaq, as the closing bid price for the Company&rsquo;s common stock was below $1.00 per share as set forth in the Nasdaq listing
      rules. After the Company was granted an extended period to regain compliance, the Company received notice from Nasdaq notifying
      the Company that it has regained compliance with Nasdaq&rsquo;s minimum bid price requirement under Nasdaq Rule&nbsp;5550(a)(2).</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
      September&nbsp;23, 2024, we received a notice from Nasdaq notifying us that we were not in compliance with the Minimum Bid Price
      Rule. On October&nbsp;31, 2024, the Company received notice from Nasdaq notifying the Company that it has regained compliance with
      Nasdaq&rsquo;s minimum bid price requirement under Nasdaq Rule&nbsp;5550(a)(2).</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Minimum
      Stockholder Equity Requirement</I></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
      the Nasdaq listing rules, we are also required to maintain stockholders&rsquo; equity of at least $2,500,000 (the &ldquo;Minimum
      Stockholder Equity Rule&rdquo;). In our Form 10-Q for the period ending March&nbsp;31, 2024, we reported stockholders&rsquo; equity
      of $2,326,987. On May&nbsp;16, 2024, we received a letter from the Listing Qualifications Department of Nasdaq notifying the Company
      that its stockholders&rsquo; equity as reported in such Quarterly Report did not satisfy the continued listing requirement under
      Nasdaq Listing Rule&nbsp;5550(b)(1) for the Nasdaq Capital Market.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
      to the Notice, the Company had 45 calendar days from the date of the Notice to submit a plan to regain compliance. On July&nbsp;1,
      2024, the Company submitted a plan to Nasdaq. As described in the Company&rsquo;s submission to Nasdaq, and as set forth in the
      Current Report on Form 8-K filed by the Company on July&nbsp;3, 2024, the Company consummated the public offering of 3 million
      shares of the Company&rsquo;s Common Stock for total aggregate gross proceeds of approximately $5,250,000. On July&nbsp;23, 2024,
      the Company received written notification from the Listing Qualifications Department of Nasdaq, confirming that, based on the information
      contained in the Company&rsquo;s Form 8-K, filed with the SEC on July&nbsp;16, 2024, the Company is now in compliance with the
      Minimum Stockholder Equity Rule.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Risks
      Related to This Offering</I></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
      have broad discretion in the use of the net proceeds from this offering.</I></B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
      management will have broad discretion in the application of the net proceeds from this offering. You will not have the opportunity,
      as part of your investment decision, to assess whether such proceeds are being used in a manner agreeable to you. You must rely
      on the judgment of our management regarding the use of the net proceeds of this offering, which may be used for corporate purposes
      that do not improve our profitability or increase the price of our shares of Common Stock. Such proceeds may also be placed in
      investments that do not produce income or that lose value. The failure to use such funds by us effectively could have a material
      adverse effect on our business, financial condition, operating results and cash flow.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
      stockholders may experience significant dilution as a result of future equity issuances and exercise of outstanding options.</I></B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
      order to raise additional capital, we may in the future offer additional shares of our Common Stock or other securities convertible
      into or exchangeable for our Common Stock at prices that may not be the same as the price per share as prior issuances of Common
      Stock. We may not be able to sell shares or other securities in any other offering at a price per share that is equal to or greater
      than the price per share previously paid by investors in this offering, and investors purchasing shares or other securities in
      the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our Common
      Stock or securities convertible into Common Stock in future transactions may be higher or lower than the prices per share for previous
      issuances of Common Stock or securities convertible into Common Stock paid by certain investors. In addition, the exercise price
      of the Warrants for the Shares may be equal to or greater than the price per share previously paid by certain investors. You will
      incur dilution upon exercise of any outstanding stock options, warrants or upon the issuance of shares of Common Stock under our
      equity incentive programs. In addition, the issuance of the Shares and any future sales of a substantial number of shares of our
      Common Stock in the public market, or the perception that such sales may occur, could adversely affect the price of our Common
      Stock. We cannot predict the effect, if any, that market sales of those shares of Common Stock or the availability of those shares
      for sale will have on the market price of our Common Stock.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
      you purchase shares in this offering, you will suffer immediate and substantial dilution of your investment.</I></B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      price per share of our common stock in this offering may exceed the net tangible book value per share of our common stock outstanding
      prior to this offering. Therefore, if you purchase shares in this offering, you may pay a price per share that substantially exceeds
      our net tangible book value per share after this offering. To the extent shares are issued under outstanding options at exercise
      prices lower than the price of our common stock in this offering, you will incur further dilution.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>It
      is not possible to predict the aggregate proceeds resulting from sales made under the ATM Sales Agreement.</I></B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
      to certain limitations in the ATM Sales Agreement and compliance with applicable law, we have the discretion to deliver a placement
      notice to the Sales Agent at any time throughout the term of the ATM Sales Agreement. The number of shares that are sold through
      the Sales Agent after delivering a placement notice will fluctuate based on a number of factors, including the market price of
      our common stock during the sales period, any limits we may set with the Sales Agent in any applicable placement notice and the
      demand for our common stock. Because the price per share of each share sold pursuant to the ATM Sales Agreement will fluctuate
      over time, it is not currently possible to predict the aggregate proceeds to be raised in connection with sales under the ATM Sales
      Agreement.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
      common stock offered hereby will be sold in &ldquo;at-the-market offerings&rdquo; and investors who buy shares at different times
      will likely pay different prices.</I></B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investors
      who purchase shares in this offering at different times will likely pay different prices, and accordingly may experience different
      levels of dilution and different outcomes in their investment results. We will have discretion, subject to market demand, to vary
      the timing, prices and number of shares sold in this offering. In addition, subject to the final determination by our board of
      directors or any restrictions we may place in any applicable placement notice, there is no minimum or maximum sales price for shares
      to be sold in this offering. Investors may experience a decline in the value of the shares they purchase in this offering as a
      result of sales made at prices lower than the prices they paid.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
      actual number of shares of common stock we will issue under the ATM Sales Agreement in this offering, at any one time or in total,
      is uncertain.</I></B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
      to certain limitations in the ATM Sales Agreement and compliance with applicable law, we have the discretion to deliver a placement
      notice to the Sales Agent at any time throughout the term of the offering under this prospectus. The number of shares of common
      stock that are sold by the Sales Agent after delivering a placement notice will fluctuate based on the market price of the shares
      of common stock during the sales period and limits we set with the Sales Agent. Because the price per share sold will fluctuate
      based on the market price of our common stock during the sales period, it is not possible at this stage to predict the number of
      common stock that will be ultimately issued or the gross proceeds to be raised in connection with those sales.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
      trading price of our common stock may be volatile, which could result in substantial losses for purchasers of our common stock
      in this offering and you could lose all or part of your investment.</I></B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      trading price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to various
      factors, some of which are beyond our control, including limited trading volume. The stock market in general and the market for
      companies in our industry in particular have experienced extreme volatility that has often been unrelated to the operating performance
      of particular companies. In addition to the factors discussed in these &ldquo;Risk Factors&rdquo; sections, these factors include:</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
            commencement, enrollment or results of our planned and future clinical trials;</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
            loss of any of our key scientific or management personnel;</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
            or legal developments in the United States, China and other countries;</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
            success of competitive products or technologies;</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
            actions taken by regulatory agencies with respect to our clinical trials or manufacturers;</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
            or developments in laws or regulations applicable to our products and preclinical program;</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
            to our relationships with collaborators, manufacturers or suppliers;</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
            results of our testing and clinical trials;</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
            safety concerns;</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
            concerning our competitors or our industry in general;</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
            or anticipated fluctuations in our operating results;</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
            in financial estimates or recommendations by securities analysts;</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
            acquisitions;</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
            results of our efforts to discover, develop, acquire or in-license additional products;</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
            trading volume of our securities on Nasdaq;</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
            of our common stock by us, our executive officers and directors or our stockholders or the anticipation that such sales may
            occur in the future;</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
            economic, political and market conditions and overall fluctuations in the financial markets in the United States or China;</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock
            market price and volume fluctuations of comparable companies and, in particular, those that operate in our industry;</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">investors&rsquo;
               general perception of us and our business; and</FONT></P>
            </TD>
         </TR>
         <TR>
            <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
            <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
            <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
            other factors described in the &ldquo;Risk Factors&rdquo; sections of our Form 10-K for the year ended December&nbsp;31,
            2024, and in subsequent filings, which are incorporated by reference into this prospectus.</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
      and other market and industry factors may cause the market price and demand for our common stock to fluctuate substantially, regardless
      of our actual operating performance, which may limit or prevent investors from selling their shares of our common stock at or above
      the price paid for the shares and may otherwise negatively affect the liquidity of our common stock. In addition, the stock market
      in general, and companies in our industry in particular, have experienced extreme price and volume fluctuations that have often
      been unrelated or disproportionate to the operating performance of these companies.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
      companies that have experienced volatility in the trading price of their shares have been the subject of securities class action
      litigation. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide
      to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage
      to our reputation or adverse changes to our business practices. Defending against litigation is costly and time-consuming and could
      divert our management&rsquo;s attention and our resources. Furthermore, during litigation, there could be negative public announcements
      of the results of hearings, motions or other interim proceedings or developments, which could have a negative effect on the market
      price of our common stock.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pro_005"></A>CAUTIONARY
      NOTE ABOUT FORWARD-LOOKING STATEMENTS</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
      prospectus, any accompanying prospectus supplement and the documents that are incorporated by reference may contain forward-looking
      statements within the meaning of the federal securities laws and the Private Securities Litigation Reform Act of 1995. Such statements
      include, but are not limited to, statements about future financial and operating results, plans, objectives, expectations and intentions,
      costs and expenses, outcome of contingencies, financial condition, results of operations, liquidity, cost savings, objectives of
      management, business strategies, clinical trial timing and plans, the achievement of clinical and commercial milestones, the advancement
      of our technologies and our products and product candidates, and other statements that are not historical facts. You can identify
      forward-looking statements by words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;could,&rdquo; &ldquo;expect,&rdquo;
      &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;planned,&rdquo; &ldquo;potential,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo;
      &ldquo;would&rdquo; or the negative of those terms or other words of similar meaning. Such forward-looking statements are inherently
      subject to known and unknown risks and uncertainties. You should read statements that contain these words carefully because they
      discuss our future expectations or state other &ldquo;forward-looking&rdquo; information. We believe that it is important to communicate
      our future expectations to our investors. However, there may be events in the future that we are not able to accurately predict
      or control and our actual results may differ materially from the expectations we describe in our forward-looking statements. Before
      you invest in the securities, you should be aware that the occurrence of the events described in Item 1A, &ldquo;Risk Factors&rdquo;
      in our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2024, and elsewhere in this prospectus, an accompanying
      prospectus supplement and in the information incorporated by reference, could have an adverse effect on our business, results of
      operations and financial condition. The forward-looking statements contained or incorporated by reference in this prospectus or
      an accompanying prospectus supplement relate only to circumstances as of the date on which the statements are made.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
      subsequent written or oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified
      in their entirety by the cautionary statements contained or referred to in this section. We do not undertake any obligation to
      release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date of this prospectus
      or to reflect the occurrence of unanticipated events, except as may be required under applicable U.S. securities law. If we do
      update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to
      those or other forward-looking statements.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pro_006"></A>USE
      OF PROCEEDS</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
      may issue and sell shares of common stock having aggregate sales proceeds of up to $3,100,000 from time to time, before deducting
      sales agent commissions and expenses. The amount of proceeds from this offering will depend upon the number of shares of our common
      stock sold and the market price at which they are sold. Because there is no minimum offering amount required as a condition of
      this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time.
      There can be no assurance that we will be able to sell any shares under or fully utilize the ATM Sales Agreement.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
      as described in the Prospectus Supplement or any related free writing prospectus that we may authorize to be provided to you, we
      currently intend to use the net proceeds from the sale of the securities offered hereby for general corporate purposes, including
      working capital, operating expenses and capital expenditures. We may also use a portion of the net proceeds to acquire or invest
      in businesses and products that are complementary to our own, although we have no current plans, commitments or agreements with
      respect to any acquisitions as of the date of this prospectus. We will set forth in the applicable prospectus supplement or free
      writing prospectus our intended use for the net proceeds received from the sale of any securities sold pursuant to the prospectus
      supplement or free writing prospectus. We intend to invest the net proceeds to us from the sale of securities offered hereby that
      are not used as described above in short-term, investment-grade, interest-bearing instruments.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pro_007"></A>DILUTION</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
      you purchase securities in this offering, your ownership interest will be diluted to the extent of the difference between the public
      offering price per share of our Common Stock and the as adjusted net tangible book value per share of our Common Stock immediately
      after giving effect to this offering.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
      net tangible book value as of December&nbsp;31, 2024, was approximately $3.4 million, or approximately $.26 per share of our Common
      Stock. Our net tangible book value is the amount of our total tangible assets minus total liabilities. Net tangible book value
      per share as of December&nbsp;31, 2024, is our net tangible book value divided by the number of shares of Common Stock outstanding
      as of December&nbsp;31, 2024.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      information below is illustrative only. Our dilution following the closing of this offering will change based on the actual public
      offering price and other terms of this offering determined at pricing. You should read this table in conjunction with &ldquo;Management&rsquo;s
      Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and the financial statements and related notes
      included in our Form 10-K for the fiscal year ended December&nbsp;31, 2024 and subsequent quarterly reports.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
      giving effect to the sale of 1,731,843 shares of our common stock pursuant to this prospectus in the aggregate amount of $3,100,000
      at an assumed price of $1.79 per share, which was the last reported sale price of our common stock on Nasdaq on May&nbsp;2, 2025,
      and net of offering expenses payable by us (estimated at $125,000), and commissions, our as adjusted net tangible book value as
      of December&nbsp;31, 2024, would have been approximately $6.3 million, or approximately $.42 per share of common stock. This amount
      represents an immediate increase in as adjusted net tangible book value of $.16 per share of common stock to our existing stockholders
      and an immediate dilution of $1.37 per share of common stock to investors participating in this offering. We determine dilution
      per share of common stock to investors participating in this offering by subtracting as adjusted net tangible book value per share
      of common stock after giving effect to this offering from the public offering price per share of common stock paid by investors
      participating in this offering.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Assumed offering price per share</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.79</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net tangible book value per share as of December&nbsp;31, 2024</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">.26</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Increase in net tangible book value per share attributable to this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">.16</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">As adjusted net tangible book value per share after giving effect to this offering</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">.42</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Dilution per share to new investors participating in this offering</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.37</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      table above assumes, for illustrative purposes, that an aggregate of 1,731,843 shares of our common stock are sold at an offering
      price of $1.79 per share, the last reported sale price of our common stock on the Nasdaq Capital Market on May&nbsp;2, 2025, for
      aggregate gross proceeds of $3,100,000. However, the shares sold in this offering, if any, will be sold from time to time at various
      prices.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      number of shares of our Common Stock outstanding is based on an aggregate of 13,303,523 shares of our Common Stock outstanding
      as December&nbsp;31, 2024, and excludes:</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,662,250
            shares of common stock issuable upon exercise of outstanding warrants issued in our initial public offering;</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,988,375
            shares of our common stock issuable upon the exercise of outstanding and vested stock options under the Company&rsquo;s 2023
            Equity Incentive Plan, as amended (the &ldquo;2023 Plan&rdquo;); and</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
            <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
            312,000 shares of our common stock that have been approved for grant under the 2023 Plan, but have not yet been issued.</FONT></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>This
      prospectus reflects and assumes no exercise of outstanding options or warrants and that all such options and warrants have been
      or will be earned.</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="pro_008"></A>PLAN
      OF DISTRIBUTION</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
      to the ATM Sales Agreement, we may issue and sell from time to time shares of our common stock having an aggregate gross sales
      price of up to $3,100,000 through the Sales Agent, acting as sales agent or principal, subject to certain limitations. The ATM
      Sales Agreement has been filed with the SEC and is incorporated by reference into this prospectus. This is a brief summary of the
      material terms of the ATM Sales Agreement and does not purport to be a complete statement of its terms and conditions.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
      time that we wish to sell common stock under the ATM Sales Agreement, we will provide an agent designated by the Company as sole
      executing agent with a placement notice describing the number or dollar value of shares to be issued, the time period during which
      sales are requested to be made, any limitation on the number of shares that may be sold in any one day, and any minimum price below
      which sales may not be made.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
      receipt of a placement notice from us, and subject to the terms and conditions of the ATM Sales Agreement, the Sales Agent have
      agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable state and
      federal laws, rules, and regulations, and the rules of Nasdaq to sell such shares up to the amount specified. The settlement between
      us and the Sales Agent of each sale will occur on the second trading day following the date on which the sale was made or on some
      other date that is agreed upon by us and the Sales Agents in connection with a particular transaction. The obligation of the Sales
      Agent under the ATM Sales Agreement to sell our common stock pursuant to a placement notice is subject to a number of conditions.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
      will pay the Sales Agent a commission of 3% of the aggregate gross proceeds from each sale of our common stock under the ATM Sales
      Agreement. The Sales Agent may also receive customary brokerage commissions from purchasers of the common stock in compliance with
      FINRA Rule&nbsp;2121. The Sales Agent may effect sales to or through dealers, and such dealers may receive compensation in the
      form of discounts, concessions or commissions from the Sales Agents and/or purchasers of shares of common stock for whom they may
      act as agents or to whom they may sell as principal. We have also agreed to reimburse Maxim for certain specified expenses, including
      actual reasonable and documented out-of-pocket costs and expenses, including the fees and disbursements of its legal counsel, in
      an amount not to exceed $70,000. In addition to such fees, at the end of each quarter in which the offering is open and during
      which sales of our common stock have occurred, we have agreed to pay Maxim&rsquo;s legal counsel an additional legal fee in an
      amount not to exceed $10,000.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      actual proceeds to us will vary depending on the number of shares sold and the prices of such sales. Because there is no minimum
      offering amount required as a condition to close this offering, the actual total public offering amount, commissions, and proceeds
      to us, if any, are not determinable at this time.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
      connection with the sale of our common stock contemplated in this prospectus, the Sales Agent will be deemed to be &ldquo;underwriter&rdquo;
      within the meaning of the Securities Act, and the compensation paid to the Sales Agent will be deemed to be underwriting commissions
      or discounts. We have agreed to indemnify the Sales Agent against certain civil liabilities, including liabilities under the Securities
      Act.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
      of our common stock as contemplated in this prospectus will be settled through the facilities of The Depository Trust Company or
      by such other means as we and the Sales Agents may agree upon. There is no arrangement for funds to be received in escrow, trust,
      or similar arrangement.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      offering of our common stock pursuant to the ATM Sales Agreement will terminate on the earlier of (1) the issuance and sale of
      all of our common stock subject to the ATM Sales Agreement, or (2) termination of the ATM Sales Agreement by us or the Sales Agent.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      Sales Agent and its affiliates may in the future provide various investment banking, commercial banking and other financial services
      for us and our affiliates, for which services they may in the future receive customary fees. To the extent required by Regulation
      M, the Sales Agent will not engage in any market making activities involving our common stock while the offering is ongoing under
      this prospectus.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
      prospectus in electronic format may be made available on a website maintained by the Sales Agent and the Sales Agent may distribute
      this prospectus electronically.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
      common stock is traded on the Nasdaq under the symbol &ldquo;NXL&rdquo;.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      foregoing does not purport to be a complete statement of the terms and conditions of the ATM Sales Agreement. A copy of the ATM
      Sales Agreement is attached hereto as an exhibit.</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><a name="pro_009"></a>LEGAL MATTERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The validity of the securities being offered hereby will be passed upon for us by Warshaw Burstein, LLP, New York, New York.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><a name="pro_010"></a>EXPERTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Marcum LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2024, as set forth in their report (which report includes an explanatory paragraph referring to the Company&rsquo;s ability to continue as a going concern) which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Marcum LLP&rsquo;s report, given on their authority as experts in accounting and auditing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><a name="pro_011"></a>WHERE YOU CAN FIND MORE INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have filed with the SEC a registration
statement on Form S-3 under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), with respect to the
securities offered by this prospectus and any applicable prospectus supplement. This prospectus and any applicable prospectus
supplement do not contain all of the information set forth in the registration statement and its exhibits and schedules in
accordance with SEC rules and regulations. For further information with respect to us and the securities being offered by this
prospectus and any applicable prospectus supplement, you should read the registration statement, including its exhibits and
schedules. Statements contained in this prospectus and any applicable prospectus supplement, including documents that we have
incorporated by reference, as to the contents of any contract or other document referred to are not necessarily complete, and, with
respect to any contract or other document filed as an exhibit to the registration statement or any other such document, each such
statement is qualified in all respects by reference to the corresponding exhibit. You should review the complete contract or other
document to evaluate these statements. You may obtain copies of the registration statement and its exhibits via the SEC&rsquo;s website at <u>http://www.sec.gov</u>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We file annual, quarterly and current reports, proxy statements and other documents with the SEC under the Exchange Act. The SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers, including us, that file electronically with the SEC. You may obtain documents that we file with the SEC at <u>http://www.sec.gov</u>. We also make these documents available on our website at <u>www.nexalin.com</u>. Our website and the information contained or accessible through our website is not incorporated by reference in this prospectus or any prospectus supplement, and you should not consider it part of this Prospectus Supplement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><a name="pro_012"></a>INFORMATION INCORPORATED BY REFERENCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">SEC rules permit us to incorporate information
by reference in this prospectus and any applicable prospectus supplement. This means that we can disclose important information to
you by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to
be part of this prospectus and any applicable prospectus supplement, except for information superseded by information contained in
this prospectus or any applicable prospectus supplement itself or in any subsequently filed incorporated document. This prospectus
and any applicable prospectus supplement incorporate by reference the documents set forth below that we have previously filed with
the SEC, other than information in such documents that is deemed to be furnished and not filed. These documents contain important
information about us and our business and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Annual Report on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1527352/000182912625001794/nexalintech_10k.htm">Form 10-K</a> for the year ended December&nbsp;31, 2024, filed with the SEC on March&nbsp;14, 2025, as amended by <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1527352/000182912625002649/nexalintech_10ka.htm">Form 10-K/A</a>, filed with the SEC on April&nbsp;15, 2025;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"></td>
    <td style="text-align: justify; width: 0.25in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The description of our common stock contained in our Registration Statement on <a href="https://www.sec.gov/Archives/edgar/data/1527352/000182912622016878/nexalintechinc_8a12b.htm">Form 8-A12B</a>, filed with the SEC on September 15, 2022, and any other amendment or report filed for the purpose of updating such description;</font></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"></td>
    <td style="text-align: justify; width: 0.25in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current Reports on Form 8-K filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1527352/000182912625000757/nexalintec_8-k.htm">February 6, 2025</a>,  <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1527352/000182912625002760/nexalintec_8-k.htm">April 17, 2025</a>, and <A HREF="http://www.sec.gov/Archives/edgar/data/1527352/000182912625003349/nexalintec_8-k.htm">May 5, 2025</A>; and</font></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">Any future filings made with the SEC under Section&nbsp;13(a), 13(c) or 15(d) of the Exchange Act.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain statements in and portions of this prospectus update and replace information in the above listed documents incorporated by reference.
Likewise, statements in or portions of a future document incorporated by reference in this prospectus may update and replace statements
in and portions of this prospectus or the above listed documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We will provide you without charge, upon your written or oral request, a copy of any of the documents incorporated by reference in this
prospectus, other than exhibits to such documents which are not specifically incorporated by reference into such documents. Please direct
your written or telephone requests to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Nexalin Technology, Inc<font style="text-transform: uppercase">.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">1776 Yorktown, Suite 550</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Houston, TX 77056</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(832) 260-0222</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our reports and documents incorporated by
reference herein may also be found in the &ldquo;Investors&rdquo; section of our website at <u>www.nexalin.com</u>. The content of our website
and any information that is linked to or accessible from our website (other than our filings with the SEC that are incorporated by
reference, as set forth under &ldquo;Incorporation of Certain Documents by Reference&rdquo;) is not incorporated by reference into this
prospectus or any applicable prospectus supplement and you should not consider it a part of this prospectus, any applicable
prospectus supplement, or the registration statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><b>PROSPECTUS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><b>NEXALIN TECHNOLOGY, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><IMG SRC="img_001.jpg" ALT="" STYLE="height: 72px; width: 250px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><b>$50,000,000 of Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may offer and sell up to an aggregate of $50,000,000 of our common stock from time to time in one or more offerings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus describes the general terms of these securities and the general manner in which these securities will be offered. We will provide you with the specific terms of any offering in one or more supplements to this prospectus. The prospectus supplements will also describe the specific manner in which these securities will be offered and may also supplement, update or amend information contained in this document. You should read this prospectus and any prospectus supplement, as well as any documents incorporated by reference into this prospectus or any prospectus supplement, carefully before you invest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our securities may be sold directly by us to you, through agents designated from time to time or to or through underwriters or dealers. For additional information on the methods of sale, you should refer to the section entitled &ldquo;Plan of Distribution&rdquo; in this prospectus and in the applicable prospectus supplement. If any underwriters or agents are involved in the sale of our securities with respect to which this prospectus is being delivered, the names of such underwriters or agents and any applicable fees, commissions or discounts and over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds that we expect to receive from such sale will also be set forth in a prospectus supplement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell our securities in public primary offerings with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million. As of April 22, 2025 the aggregate market value of our outstanding common stock held by non-affiliates, or the public float, was approximately $29,333,474, based on 10,824,160 shares of our outstanding common stock that were held by non-affiliates on such date and a price of $2.71 per share, which was the price at which our common stock was last sold on the Nasdaq Capital Market on February 28, 2025, calculated in accordance with General Instruction I.B.6 of Form S-3. We have not offered any securities pursuant to General Instruction I.B.6 of Form S-3 during the twelve-month period that ends on and includes the date hereof. Our common stock is listed on The Nasdaq Capital Market under the symbol &ldquo;NXL.&rdquo;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">On April 22, 2025, the last reported sale price of our common stock was $1.74 per share. The applicable prospectus supplement will contain information, where applicable, as to any other listing, if any, on The Nasdaq Capital Market or any securities market or other securities exchange of the securities covered by the prospectus supplement. Prospective purchasers of our securities are urged to obtain current information as to the market prices of our securities, where applicable.</p>

<p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</p>

<!-- Field: Page; Sequence: 18; Options: NewSection -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin: 0pt">&nbsp;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should carefully consider the risks that we have described on page 5 of this prospectus under the caption &ldquo;Risk Factors.&rdquo; We may include specific risk factors in supplements to this prospectus under the caption &ldquo;Risk Factors.&rdquo; This prospectus may not be used to sell our securities unless accompanied by a prospectus supplement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Currently, we are an &ldquo;emerging growth company&rdquo; as defined in Section&nbsp;2(a) of the Securities Act of 1933, as amended, and are subject to reduced public company reporting requirements. Please read &ldquo;Implications of Being an Emerging Growth Company.&rdquo;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><b>The date of this prospectus is April 23, 2025</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 19 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin: 0pt">&nbsp;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><b><font style="text-transform: uppercase">TABLE OF CONTENTS</font></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Page</b></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 90%"><A HREF="#a_001">ABOUT THIS PROSPECTUS</A></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 9%; text-align: center">1</td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><A HREF="#a_002">CAUTIONARY NOTE ABOUT FORWARD-LOOKING-STATEMENTS</A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">2</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><A HREF="#a_003">ABOUT NEXALIN TECHNOLOGY, INC.</A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">3</td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><A HREF="#a_004">RISK FACTORS</A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">5</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><A HREF="#a_005">USE OF PROCEEDS</A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">6</td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><A HREF="#a_006">DESCRIPTION OF COMMON STOCK</A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">7</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><A HREF="#a_007">PLAN OF DISTRIBUTION</A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">11</td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><A HREF="#a_008">LEGAL MATTERS</A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">13</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><A HREF="#a_009">EXPERTS</A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">13</td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><A HREF="#a_010">WHERE YOU CAN FIND MORE INFORMATION</A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">13</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><A HREF="#a_011">INFORMATION INCORPORATED BY REFERENCE</A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">14</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 20; Options: NewSection -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><b><font style="text-transform: uppercase"><a name="a_001"></a>ABOUT THIS PROSPECTUS</font></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, (the &ldquo;SEC&rdquo;), using a &ldquo;shelf&rdquo; registration process. Under this shelf registration process, we may offer and sell from time to time any combination of the securities described in this prospectus in one or more offerings in amounts, at prices and on terms that we determine at the time of the offering, with an aggregate offering price of up to $50,000,000. This prospectus provides you with a general description of the securities we may offer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Each time we offer securities, we will provide a prospectus supplement that describes the terms of the relevant offering. The prospectus supplement also may add, update or change information contained in this prospectus. Before making an investment decision, you should read carefully both this prospectus and any prospectus supplement together with the documents incorporated by reference into this prospectus as described below under the heading &ldquo;Information Incorporated by Reference.&rdquo;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">You should read both this prospectus and any accompanying prospectus supplement together with the additional information incorporated by reference. See &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Information Incorporated by Reference.&rdquo; We have not authorized anyone to provide you with different information. You should not assume that the information in this prospectus or any supplement to this prospectus is accurate at any date other than the date indicated on the cover page of these documents or the filing date of any document incorporated by reference, regardless of its time of delivery. We are not making an offer to sell the securities in any jurisdiction where the offer or sale is not permitted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">We may sell our securities to or through underwriters, dealers or agents, directly to purchasers or through a combination of any of these methods of sale, as designated from time to time. We and our agents reserve the sole right to accept or reject in whole or in part any proposed purchase of our securities. An applicable prospectus supplement, which we will provide each time we offer the securities, will set forth the names of any underwriters, dealers or agents involved in the sale of our securities, and any related fee, commission or discount arrangements. See &ldquo;Plan of Distribution.&rdquo;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">This summary highlights selected information from this prospectus and does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the heading &ldquo;Risk Factors&rdquo; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">In this prospectus, unless the context requires otherwise, references to &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;Nexalin&rdquo; or the &ldquo;Company&rdquo; refer to Nexalin Technology, Inc. and, where appropriate, its subsidiaries. Additionally, references to the &ldquo;Board&rdquo; refer to the board of directors of Nexalin Technology, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 21; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><b><font style="text-transform: uppercase"><a name="a_002"></a>CAUTIONARY NOTE ABOUT FORWARD-LOOKING STATEMENTS</font></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus, any accompanying prospectus supplement and the documents that are incorporated by reference may contain &ldquo;forward-looking statements&rdquo; as that term is defined in the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Such statements include, but are not limited to, statements about future financial and operating results, plans, objectives, expectations and intentions, costs and expenses, outcome of contingencies, financial condition, results of operations, liquidity, cost savings, objectives of management, business strategies, clinical trial timing and plans, the achievement of clinical and commercial milestones, the advancement of our technologies and our products and product candidates, and other statements that are not historical facts. You can identify&nbsp;forward-looking&nbsp;statements by words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;could,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;planned,&rdquo; &ldquo;potential,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; or the negative of those terms or other words of similar meaning.&nbsp;Such forward-looking statements are inherently subject to known and unknown risks and uncertainties.&nbsp;You should read statements that contain these words carefully because they discuss our future expectations or state other &ldquo;forward-looking&rdquo; information. We believe that it is important to communicate our future expectations to our investors. However, there may be events in the future that we are not able to accurately predict or control and our actual results may differ materially from the expectations we describe in our forward-looking statements. Before you invest in the securities, you should be aware that the occurrence of the events described in Item 1A, &ldquo;Risk Factors&rdquo; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and elsewhere in this prospectus, an accompanying prospectus supplement and in the information incorporated by reference, could have an adverse effect on our business, results of operations and financial condition. The forward-looking statements contained or incorporated by reference in this prospectus, or an accompanying prospectus supplement relate only to circumstances as of the date on which the statements are made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All subsequent written or oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We do not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date of this prospectus or to reflect the occurrence of unanticipated events, except as may be required under applicable U.S. securities law. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><b><font style="text-transform: uppercase"><a name="a_003"></a>ABOUT NEXALIN tECHNOLOGY, INC.</font></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Our Company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a medical device company engaged in the design and developments of innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. We developed an easy-to-administer medical device &mdash; referred to as &ldquo;Generation 1&rdquo; or &ldquo;Gen-1&rdquo; &mdash; that utilizes bioelectronic medical technology to treat anxiety, insomnia and depression without the need for drugs or psychotherapy. Our original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (the &ldquo;FDA&rdquo;) as a Class II device.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Medical professionals in the United States have utilized the Gen-1 device to administer treatment to patients in clinical settings. While the Gen-1 device had been cleared by the FDA to treat depression, anxiety, and insomnia, three prevalent and serious diseases, because of the FDA&rsquo;s December&nbsp;2019 reclassification of CES devices, the Gen-1 device was reclassified as a Class II device for the treatment of anxiety and insomnia. We are required to file a new application under Section&nbsp;510(k) of the Federal Food, Drug and Cosmetic Act (&ldquo;510(k) Application&rdquo;) to be approved by the FDA for the sales and marketing of our devices for the treatment of anxiety and insomnia. In the FDA&rsquo;s December&nbsp;2019 reclassification ruling, the treatment of depression with our device will require a Class III certification and require a new PMA (premarket approval) and/or a new De Novo application to demonstrate safety and effectiveness.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While we continue providing services to medical professionals to support patients&rsquo; use of the Gen-1 devices which were in operation prior to December&nbsp;2019, we are not making new sales or new marketing efforts of Gen-1 devices in the United States. We continue to derive revenue from devices which we sold or leased prior to the FDA&rsquo;s December&nbsp;2019 reclassification announcement. This revenue consists of monthly licensing fees and payments for the sale of electrodes and patient cables. We have paused marketing efforts for new sales of our Gen-1 device for treatment of anxiety and insomnia in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The waveform that comprises the basis of our &ldquo;Generation 2&rdquo; or &ldquo;Gen-2&rdquo; and new &ldquo;Generation 3&rdquo; or &ldquo;Gen-3&rdquo; headset devices is in Q-submission process for review by the FDA. This process allows Nexalin to get clear, specific, written feedback from the FDA on indications, device classification and clarity on the regulatory pathway and improves the efficiency and predictability of the regulatory pathway. The University of California, San Diego conducted a clinical study evaluating Nexalin&rsquo;s Gen-2 tACS device, which provided positive results in reducing pain in veteran patients with Mild Traumatic Brain Injury (mTBI). We plan to conduct clinical trials for the Gen-3 device in the U.S. and we continue to consult with the FDA as part of the pre-submission process. If and when we obtain FDA clearance for the Gen-3 device, we intend to extend the development and commercialization of our devices for sale in the U.S. and other territories, given the potential unmet demand for the treatment of mental health conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All determinations of the safety and efficacy of our devices in the United States are solely within the purview of the FDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant aspects of our ongoing operations and clinical trials and development programs are conducted in China, through a joint venture entity formed under the laws of Hong Kong, Nexalin Neurohealth Company Limited (&ldquo;Joint Venture&rdquo;), with Wider Come Limited (&ldquo;Wider&rdquo;). We own 48% of the equity of the Joint Venture entity, and Wider owns 52% of such equity. In September of 2021, the China National Medical Products Administration (the &ldquo;NMPA&rdquo;), the equivalent of the FDA, approved the Gen-2 device for marketing and sale in China for the treatment of insomnia and depression. These treatment indications and clearances from the NMPA have allowed Wider to market and sell the Gen-2 device in China for the treatment of insomnia and depression.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to our core business model, we have also formed a Military &amp; Government Advisory Board aimed at fostering and enhancing relationships within and throughout United States federal government and public sector organizations, including the U.S. Department of Defense, U.S. Department of Veterans Affairs, and U.S. Department of Health and Human Services. In conjunction with our ongoing clinical trials, our goals include the broad deployment of our devices within the U.S. military and government agencies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Corporate Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">We were incorporated in the state of Nevada on October&nbsp;19, 2010, and redomiciled in Delaware on December&nbsp;21, 2021. Our principle executive office is located at 1776 Yorktown, Suite 550, Houston, Texas 77056, and our telephone number is (832) 260-0222. Our website address is <u>www.nexalin.com</u>. The information contained on or accessible through our website is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus or in deciding whether to purchase our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Implications of Being an Emerging Growth Company and Smaller Reporting Company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">We are an &ldquo;emerging growth company,&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012 (the &ldquo;JOBS Act&rdquo;). We will remain an emerging growth company until the earlier of (i) the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;); (ii) the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under applicable SEC rules. We expect that we will remain an emerging growth company for the foreseeable future, but cannot retain our emerging growth company status indefinitely and will no longer qualify as an emerging growth company on or before the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement under the Securities Act. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from specified disclosure requirements that are applicable to other public companies that are not emerging growth companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">These exemptions include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &ldquo;<i>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</i>&rdquo; disclosure;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&rsquo;s report providing additional information about the audit and the financial statements;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">reduced disclosure obligations regarding executive compensation; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">not being required to hold a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">We have taken advantage of certain reduced reporting requirements in this prospectus. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">An emerging growth company can take advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected to avail ourselves of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the dates on which adoption of such standards is required for other public reporting companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">We are also a &ldquo;smaller reporting company&rdquo; as defined in Rule&nbsp;12b-2 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), and have elected to take advantage of certain of the scaled disclosure available for smaller reporting companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<br> </p>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><b><a name="a_004"></a>RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>Investing in our securities involves a high degree of risk. You should carefully consider the risks described in the documents incorporated by reference in this prospectus and any prospectus supplement, as well as other information we include or incorporate by reference into this prospectus and any applicable prospectus supplement, before making an investment decision. Our business, financial condition or results of operations could be materially adversely affected by the materialization of any of these risks. The trading price of our securities could decline due to the materialization of any of these risks, and you may lose all or part of your investment. This prospectus and the documents incorporated herein by reference also contain forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks described in the documents incorporated herein by reference, including the risks described in Part I, Item 1A, Risk Factors in our most recent Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2024, together with the other information set forth in this prospectus, and in the other documents that we include or incorporate by reference into this prospectus, as updated by our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings we make with the SEC, the risk factors described under the caption &ldquo;Risk Factors&rdquo; in any applicable prospectus supplement and any risk factors set forth in our other filings with the SEC pursuant to Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act, before making a decision about investing in our common stock. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. If any risks actually occur, our business, financial condition and results of operations may be materially and adversely affected. In such an event, the trading price of our common stock could decline and you could lose part or all of your investment.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">For more information about our SEC filings, please see &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation by Reference.&rdquo;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Additional risks not presently known or that we presently consider to be immaterial could subsequently materially and adversely affect our financial condition, results of operations, business, and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><b><font style="text-transform: uppercase"><a name="a_005"></a>USE OF PROCEEDS</font></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. Except as described in any prospectus supplement or any related free writing prospectus that we may authorize to be provided to you, we currently intend to use the net proceeds from the sale of the securities offered hereby for general corporate purposes, including working capital, operating expenses and capital expenditures. We may also use a portion of the net proceeds to acquire or invest in businesses and products that are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus. We will set forth in the applicable prospectus supplement or free writing prospectus our intended use for the net proceeds received from the sale of any securities sold pursuant to the prospectus supplement or free writing prospectus. We intend to invest the net proceeds to us from the sale of securities offered hereby that are not used as described above in short-term, investment-grade, interest-bearing instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><b><font style="text-transform: uppercase"><a name="a_006"></a>DESCRIPTION OF COMMON STOCK</font></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><i>The following description of our common stock and certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries. You should also refer to the amended and restated certificate of incorporation and bylaws, which are filed as exhibits to the registration statement of which this prospectus is part.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>General</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The following summary sets forth some of the general terms of our common stock. Because this is a summary, it does not contain all of the information that may be important to you. For a more detailed description of our common stock, you should read our amended and restated certificate of incorporation and the amended and restated bylaws, each of which is an exhibit to our Annual Report on Form 10-K and the applicable provisions of the Delaware General Corporation Law (the &ldquo;DGCL&rdquo;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Our Certificate of Incorporation, as amended to date, we are authorized to issue 100,000,000 shares of common stock, $0.001 par value per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Outstanding Shares</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">As of April 22, 2025, we had 13,327,929 shares of common stock outstanding, held of record by 828 stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Voting Rights</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders. The affirmative vote of holders of at least 66% of the voting power of all of the then-outstanding shares of capital stock, voting as a single class, will be required to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to amending our amended and restated bylaws, the classified board, the size of our board, removal of directors, director liability, vacancies on our board, special meetings, stockholder notices, actions by written consent and exclusive forum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Dividends</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Holders of our common stock are entitled to receive ratably any dividends that our board of directors may declare out of funds legally available for that purpose.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Liquidation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">In the event of our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Rights and Preferences</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Holders of our common stock have no pre-emptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Fully Paid and Nonassessable</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">All outstanding shares of our common stock are fully paid and non-assessable, and the shares of common stock to be issued upon completion of this offering will be fully paid and non-assessable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Anti-Takeover Provisions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Certificate of Incorporation and Bylaws to be in Effect Immediately Prior to Completion of this Offering</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Our amended certificate of incorporation and amended and restated bylaws:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">provide that the authorized number of directors may be changed only by resolution of our board of directors;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">provide that directors may only be removed for cause, which removal may be effected, subject to any limitation imposed by law, by the holders of at least 66% of the voting power of all of our then-outstanding shares of the capital stock entitled to vote generally at an election of directors;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in; text-align: justify">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent or electronic transmission;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&rsquo;s notice;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">provide that special meetings of our stockholders may be called only by the chairman of our board of directors, our chief executive officer or president or by our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election if they should so choose.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The amendment of any of these provisions would require approval by the holders of at least 66% of the voting power of all our then-outstanding common stock entitled to vote generally in the election of directors, voting together as a single class.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The combination of these provisions will make it more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Because our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce our vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of delaying changes in our control or management. As a consequence, these provisions may also inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts. We believe that the benefits of these provisions, including increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure our company, outweigh the disadvantages of discouraging takeover proposals, because negotiation of takeover proposals could result in an improvement of their terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b><i>Section&nbsp;203 of the Delaware General Corporation Law</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">We are subject to Section&nbsp;203 of the DGCL, which prohibits a Delaware corporation from engaging in a business combination with any interested stockholder for a period of three years following the date the person became an interested stockholder, with the following exceptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested holder;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (a) by persons who are directors and also officers and (b) pursuant to employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66% of the outstanding voting stock that is not owned by the interested stockholder.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">In general, Section&nbsp;203 of the DGCL defines business combination to include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">any merger or consolidation involving the corporation and the interested stockholder;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits by or through the corporation.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">In general, Section&nbsp;203 of the DGCL defines an &ldquo;interested stockholder&rdquo; as an entity or person who, together with the entity&rsquo;s or person&rsquo;s affiliates and associates, beneficially owns, or is an affiliate of the corporation and within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">A Delaware corporation may &ldquo;opt out&rdquo; of these provisions with an express provision in its certificate of incorporation. We have not opted out of these provisions, which may as a result, discourage or prevent mergers or other takeover or change of control attempts of us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Choice of Forum</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us or any of our directors, officers, employees or agents arising under the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws; any action or proceeding to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws; and any action asserting a claim against us that is governed by the internal affairs doctrine. Our amended and restated certificate of incorporation further provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. The enforceability of similar choice of forum provisions in other companies&rsquo; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with one or more actions or proceedings described above, a court could find the choice of forum provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Transfer Agent and Registrar</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Our transfer agent and registrar for our common stock and warrants is Continental Stock Transfer &amp; Trust Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><b>Exchange Listing</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Our common stock is listed on the Nasdaq Capital Market under the symbol &ldquo;NXL.&rdquo;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><b><a name="a_007"></a>PLAN OF DISTRIBUTION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">We may sell the securities covered by this prospectus directly to purchasers or through underwriters, broker-dealers, or agents, who may receive compensation in the form of discounts, concessions, or commissions from us. These discounts, concessions, or commissions as to any particular underwriter, broker-dealer, or agent may be in excess of those customary in the types of transactions involved. In addition, we may issue the securities as a dividend or distribution or in a subscription rights offering to our existing stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The securities may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of sale, at varying prices determined at the time of sale, or at negotiated prices. These sales may be effected in transactions which may involve crosses or block transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">If underwriters are used in an offering of securities, such offered securities may be resold in one or more transactions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">on any national securities exchange or quotation service on which the common stock may be listed or quoted at the time of sale, including, as of the date of this prospectus, the Nasdaq Capital Market in the case of the common stock;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">in the over-the-counter market;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">in transactions otherwise than on these exchanges or services or in the over-the-counter market; or</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top; text-align: justify">through the writing of options, whether the options are listed on an options exchange or otherwise.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Each prospectus supplement will state the terms of the offering, including, but not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top">the names of any underwriters, dealers, or agents;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top">the public offering or purchase price of the securities and the net proceeds that we will receive from the sale;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top">any underwriting discounts and commissions or other items constituting underwriters&rsquo; compensation;</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top">any discounts, commissions, or fees allowed or paid to dealers or agents; and</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 0.25in">&nbsp;</td>
    <td style="vertical-align: top; width: 0.25in">&#9679;</td>
    <td style="vertical-align: top">any securities exchange on which the offered securities may be listed.</td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">If we sell securities to underwriters, we will execute an underwriting agreement with them at the time of the sale and will name them in the applicable prospectus supplement. In connection with these sales, the underwriters may be deemed to have received compensation in the form of underwriting discounts and commissions. The underwriters also may receive commissions from purchasers of securities for whom they may act as agent. Unless we specify otherwise in the applicable prospectus supplement, the underwriters will not be obligated to purchase the securities unless the conditions set forth in the underwriting agreement are satisfied, and if the underwriters purchase any of the securities offered by such prospectus supplement, they will be required to purchase all of such offered securities. The underwriters may acquire the securities for their own account and may resell the securities from time to time in one or more transactions, including negotiated transactions, at a fixed public offering price or varying prices determined at the time of sale. The underwriters may sell the securities to or through dealers, and those dealers may receive discounts, concessions, or commissions from the underwriters as well as from the purchasers for whom they may act as agent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may designate agents who agree to use their reasonable efforts to solicit purchasers for the period of their appointment or to sell securities on a continuing basis. We may also sell securities directly to one or more purchasers without using underwriters or agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Under agreements entered into with us, underwriters and agents may be entitled to indemnification by us against certain civil liabilities, including liabilities under the Securities Act, or to contribution for payments the underwriters or agents may be required to make. The underwriters, agents, and their affiliates may engage in financial or other business transactions with us and our subsidiaries in the ordinary course of business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The aggregate proceeds to us from the sale of the securities will be the purchase price of the securities less discounts and commissions, if any.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">In order to facilitate the offering of the securities, any underwriters may engage in transactions that stabilize, maintain, or otherwise affect the price of the securities or any other securities the prices of which may be used to determine payments on such securities. Specifically, any underwriters may over allot in connection with the offering, creating a short position for their own accounts. In addition, to cover overallotments or to stabilize the price of the securities or of any such other securities, the underwriters may bid for, and purchase, the securities or any such other securities in the open market. Finally, in any offering of the securities through a syndicate of underwriters, the underwriting syndicate may reclaim selling concessions allowed to an underwriter or a dealer for distributing the securities in the offering if the syndicate repurchases previously distributed securities in transactions to cover syndicate short positions, in stabilization transactions, or otherwise. Any of these activities may stabilize or maintain the market price of the securities above independent market levels. Any such underwriters are not required to engage in these activities and may end any of these activities at any time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The applicable prospectus supplement may provide that the original issue date for your securities may be more than three scheduled business days after the trade date for your securities. Accordingly, in such a case, if you wish to trade securities on any date prior to the third business day before the original issue date for your securities, you will be required, by virtue of the fact that your securities initially are expected to settle in more than three scheduled business days after the trade date for your securities, to make alternative settlement arrangements to prevent a failed settlement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The securities may be new issues of securities and may have no established trading market. The securities may or may not be listed on a national securities exchange. We can make no assurance as to the liquidity of or the existence of trading markets for any of the securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">In order to comply with the securities laws of some states, if applicable, the shares of common stock offered by this prospectus must be sold in such jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the shares of common stock may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">To the extent required, this prospectus may be amended or supplemented from time to time to describe a specific plan of distribution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><b><a name="a_008"></a>LEGAL MATTERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The validity of the securities being offered hereby will be passed upon for us by Warshaw Burstein, LLP, New York, New York.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><b><a name="a_009"></a>EXPERTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Marcum LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2024, as set forth in their report (which report includes an explanatory paragraph referring to the Company&rsquo;s ability to continue as a going concern) which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Marcum LLP&rsquo;s report, given on their authority as experts in accounting and auditing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><b><a name="a_010"></a>WHERE YOU CAN FIND MORE INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">We have filed with the SEC a registration
statement on Form S-3 under the Securities Act with respect to the
securities offered by this prospectus and any applicable prospectus supplement. This prospectus and any applicable prospectus
supplement do not contain all of the information set forth in the registration statement and its exhibits and schedules in
accordance with SEC rules and regulations. For further information with respect to us and the securities being offered by this
prospectus and any applicable prospectus supplement, you should read the registration statement, including its exhibits and
schedules. Statements contained in this prospectus and any applicable prospectus supplement, including documents that we have
incorporated by reference, as to the contents of any contract or other document referred to are not necessarily complete, and, with
respect to any contract or other document filed as an exhibit to the registration statement or any other such document, each such
statement is qualified in all respects by reference to the corresponding exhibit. You should review the complete contract or other
document to evaluate these statements. You may obtain copies of the registration statement and its exhibits via the SEC&rsquo;s website at <u>http://www.sec.gov</u>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">We file annual, quarterly and current reports, proxy statements and other documents with the SEC under the Exchange Act. The SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers, including us, that file electronically with the SEC. You may obtain documents that we file with the SEC at <u>http://www.sec.gov</u>. We also make these documents available on our website at <u>www.nexalin.com</u>. Our website and the information contained or accessible through our website is not incorporated by reference in this prospectus or any prospectus supplement, and you should not consider it part of this prospectus or any prospectus supplement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><b><a name="a_011"></a>INFORMATION INCORPORATED BY REFERENCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">SEC rules permit us to incorporate information
by reference in this prospectus and any applicable prospectus supplement. This means that we can disclose important information to
you by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to
be part of this prospectus and any applicable prospectus supplement, except for information superseded by information contained in
this prospectus or any applicable prospectus supplement itself or in any subsequently filed incorporated document. This prospectus
and any applicable prospectus supplement incorporate by reference the documents set forth below that we have previously filed with
the SEC, other than information in such documents that is deemed to be furnished and not filed. These documents contain important
information about us and our business and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"></td>
    <td style="text-align: justify; width: 0.25in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual Report on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1527352/000182912625001794/nexalintech_10k.htm">Form 10-K</a> for the year ended December 31, 2024, filed with the SEC on March 14, 2025, as amended by <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1527352/000182912625002649/nexalintech_10ka.htm">Form 10-K/A</a>, filed with the SEC on April 15, 2025;</font></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"></td>
    <td style="text-align: justify; width: 0.25in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The description of our common stock contained in our Registration Statement on <a href="https://www.sec.gov/Archives/edgar/data/1527352/000182912622016878/nexalintechinc_8a12b.htm">Form 8-A12B</a>, filed with the SEC on September 15, 2022, and any other amendment or report filed for the purpose of updating such description;</font></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"></td>
    <td style="text-align: justify; width: 0.25in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current Reports on Form 8-K filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1527352/000182912625000757/nexalintec_8-k.htm">February 6, 2025</a> and <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1527352/000182912625002760/nexalintec_8-k.htm">April 17, 2025</a>; and</font></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"></td>
    <td style="text-align: justify; width: 0.25in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any future filings made with the SEC under Section 13(a), 13(c) or 15(d) of the Exchange Act.</font></td></tr>
  </table>

<p style="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Certain statements in and portions of this prospectus update and replace information in the above listed documents incorporated by reference. Likewise, statements in or portions of a future document incorporated by reference in this prospectus may update and replace statements in and portions of this prospectus or the above listed documents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">We will provide you without charge, upon your written or oral request, a copy of any of the documents incorporated by reference in this prospectus, other than exhibits to such documents which are not specifically incorporated by reference into such documents. Please direct your written or telephone requests to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0">Nexalin Technology, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0">1776 Yorktown, Suite 550</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0">Houston, TX 77056</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0">(832) 260-0222</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Our reports and documents incorporated by reference herein may also be found in the &ldquo;Investors&rdquo; section of our website at <u>www.nexalin.com</u>. The content of our website and any information that is linked to or accessible from our website (other than our filings with the SEC that are incorporated by reference, as set forth under &ldquo;Incorporation of Certain Documents by Reference&rdquo;) is not incorporated by reference into this prospectus or any applicable prospectus supplement and you should not consider it a part of this prospectus, any applicable prospectus supplement, or the registration statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></DIV>

    <!-- Field: /Page -->


   </BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>img_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !J 6\# 2(  A$! Q$!_\0
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M-->T4F<\Y/D:1GX '7K^E&,8ZX/>DSM!R,X^;\*[#PWX N_$.F_;6G\F-ON
M]Z]&K5C#66QYM.BZFB.0'WN>F.M>A_"S0#<W3ZQ.OR1_+&I'?UJ0_"&=AAM1
M7!/(%>DZ-I46CZ9#9Q 8C7!([GUKR\5C(RCRP/0P^$<)7D6[@ VTW^X?Y5XK
MX/T^+6-:UNQFP0T9*?7->UW'_'K-_N-_*O(?AM@^--0XSUP?QKFPTG&$VNQT
MXF*E**\ROX*UF;PMXDETB_+)#(^PJ>BG/!KVA6# $'(/ZUYE\3_##2JNN6JG
MS(P!*%[^AK7^'GB;^V-,^QSN/M=L #GJ1ZTJT5."JQ"G)TY<C.0UW_DK,0S_
M !I7LJ] :\:U_P"7XLPYX^9/QKV91P*,6K<G:Q5!?O)/S/$?B!_R4!1U.Y,"
MO:;3 LX?^N:_RKQ/XBEAXX;R^)"%VGWK0CM/B((D\LR!,#: >U;5*7-3A>5C
M"%3EG)I'L/XTT@E<=J\EBM?B+]IC+/+LW#=TZ9YKUF#=Y$8D^^%&X>]<52BJ
M>J=SMIU7-ZJUC,\1:-#KVBSV<R@EAE">Q[5Y?X%U:7PUXEFT;4&*1NQ4[N@/
M:O9CTQBO'/BG#8V^LPRQ,/M;K^\5.H]#6V%E[2])[,QQ*Y7[1$7B^_N/%WB^
M+1[)BT4;;>.GN:]8T72H-&TR"R@0 1J 2.Y]:\X^$T=@T]U([ ZACY2W7'>O
M55)Z>GZT8I\C]DN@L,E)>U8\#'3O7/>-=6_L?PS=3@_.XV+[$UT).!7E'Q7U
M(W-Y9Z/"W)8-)66'I^TJ**-J\^2FV'PY\/K>^'=3NIEW&Z#(,_G5#X;WKZ/X
MHN-(F.!(Q7'H<UZ7X<M[72- L[198QLC&[YAR37EOC%!H'CN/4K9EV2N'RIZ
M'TKLA*564J;V9PRIPA&,D]4>V=!5/6.-&O"/^>3?RJ6RN5O+&"X7&)$#5%K'
M_(%O/^N3?RKSHJTK'I2=XMGE?PH_Y&&^]QS7L0KQWX4?\C#>_2O8A75C/XGR
M.?"? (:P_%_/A74/^N9K<-8GB_\ Y%74?^N9KFI?&O4WJ?"_0X?X/?ZN^_WJ
M]$UP9T.\_P"N1_E7G?P>_P!7??[U>B:W_P @2\_ZY'^5=.(_C_<<]'^ >/>#
M-'CU[2=7LS_K1ED/H<U?^'/B*31M4ET+4"41G*IN_A:I_A%_R$-3]Q_6F_$O
MPX]E=KKUFI XW[?X6]:Z9S4ING+J<T(<L541ZT.IYS[5X@QQ\2KTCJ V*]'\
M"^(UU[18UD<&[A4+*/7WKSJ5"OQ+O5'/#&HPD7"HX]37$34H*1[ABDQ3J3%>
M9;0] IZE80ZIIEQ93J&252G/K7RAK.FR:-KEYITRE3"Y"D]Q7UWMKQ3XV>'"
MDMOKL$?RG]W-@?D:ZL//E=F85HW1Y$/N@&C[O/:@\DDG QQ2I&\LD448S)(P
M51[FO3>USC2U/3?@SX=:_P!:GUJ>/]Q;KLBR/XO6O>:Y_P $Z GA[PM:66/W
MFT/(?4FNAQ7CU9<TG<]"G&R&.BRQLCC*L-I!KY?\?:$= \875J$*V\Q,D1[8
M-?4>T5YI\8_#AU/P^FHP)F:S.YB.I6M*$^65B*T;Q/ @<A2/7!K?\'7Z6FLF
MVN&_T2\4Q,#TR>AKGU.X*W0&@EE974X92"/;'>O4UN<5E:QW5GH4MUXC31@"
M2),%A_=KZ"T^PBTZPAM(1M2)0..]<9\.;.WU+3(?$3Q$74B>4<]/EXR*[_'&
M*\[%5W4?+T1TX>DH*XHI*7%(>*XK65D=1%<_\>LW^XW\J\A^&O\ R.NH?C_.
MO7+HD6LN?[A_E7D7PU(/C;4,'UX(]Z[J-O9S]#CK:U(VZ,]?N;>.ZMW@E4,C
MC:P/I7A]U;7/@'QM'(I;[.SY7T9#US]*]T//%<OXW\.+K^BR*B@7,8W1MWJ,
M-42ERRV9>(A=<RW.!UR5;GXFV-Y"0T4PC(KV<=!7SGH,LO\ PE%A!.S>;#,$
M*D>]?18/'/:M<8E[L5LD8X1OWFSQ'X@'/Q 7ZI7M5J?]$@_ZYK_*O$OB),L?
MCLN3]P*Y'L*ZV'XLZ.D$:&"4E5 -54IRG3BXK85.HH3ES/<]%Y]:#7GI^+NC
M 9^SS5V.CZM'K.E0ZA A$<HR 3T%<4J4H*[1V1JQD]&+K.J0Z-I<][.X"QJ2
M,]SVKRCP?ILOB_Q3/JVH(7MT).&Z9/04[XB>('US6HM"LFW*K8;'0M7I7A?0
MH]"T2"U4?O,;I#W)KJC:A2=OB9SW=65NB/*=;M;GP+XS6[@#"V=]ZXZ8[BO9
M--U"'4]/ANX&#1R*#QV-8_C3P^NOZ'+&JC[1&-T9]ZX7X9^(_P"S=0FT&]8K
MN;"%N@8=J<TJM+G7Q+<B%Z=3D^R>N2R+'&[N<*@R37A-Q;W7C?QK="V;:,D!
MSV KU/QOJZ:3X:N&9]KRC8GU-<E\)-+)2ZU61>7.V,^H[T8?]W3=3KT'6O4F
MH=" _##73_S&0?Q/%8WB/P-JFC::;VYO%N8T.".<CWKW!EYR"15#7-/34]'N
MK1QGS(S^=32Q<^:['5PL>6Z.<^&FK?VCX:6WD/[VV.SD]1ZUU&K_ /('O/\
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@Y8)!ZD^IJUJ0SIMSG_GF:?8C%A;X_P">:_RJ5L%C_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
